Selective β2 Agonist. Salbutamol 5 mg/ml. Sol. for inhal.
Intermittent tmt – Can be given up to 4 times/d.
Adlts and adolesc. aged 12 years and over – 0.5 ml to 1 ml (2.5 to 5 mg salbutamol). Some pts. may req. up to 2 ml (10 mg salbutamol).
Childr. aged 18 months to 12 years – 0.5 ml to 1 ml (2.5 to 5 mg salbutamol).
tmt. of sev. acute asthma (status asthmaticus) and other forms of bronchospasm
C/I: Hypersens.
Estrogen Receptor Antagonist. Elacestrant 86 mg, 345 mg. FC tab 86/345 mg
345 mg once dly until dis. progress. or unaccept. tox.
tmt. of postmenopausal women or adlt. men with estrogen recept. (ER)-pos., human epidermal growth fact. recept. 2 (HER)-neg., ESR1-mutated adv. or metast. breast cancer with dis. progr. follow. at least 1 line of endocr. ther.
C/I: Hypersens.
Atypical Antipsychotic. Risperidone 25 mg, 37.5 mg, 50 mg. Powder + solv. for PR Susp. for IM Inj.Vial 25 mg, 37.5 mg, 50mg
FONT
should be administered every 2 weeks by deep intramuscular (IM) deltoid or gluteal injection
treatment of schizophrenia is 25 mg IM every 2 weeks. monotherapy or adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder is 25 mg IM every 2 weeks. maximum dose should not exceed 50 mg/ 2w
-for tmt. of schizophrenia and schizoaffective disords.
- as monother.for maint. tmt. of bipolar I disord. to delay
occurr. of mood episodes.
- for adjunct. maint. tmt. to delay occurr. of mood episodes in pts. with freq. relapsing bipolar disord.
C/I: Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone
Monoclonal Antibody. Trastuzumab 150 mg, Trastuzumab 420 mg. Vial:Pwd. for conc. for sol for infus.
Load: 4-8 mg/kg BW
Maint. 2-6 mg/kg BW weekly or at 3 weekly interval, see lit.
Tmt. of pts. with metast. breast cancer who have tumours that overexpress HER2; 1. As a sgle. agent, for the tmt. of those pts. who have received one or more chemother. regimens for their metast. dis..2. In combin. with Paclitaxel or Docetaxel for the tmt. of those pts. who have not received chemother. for their metastatic dis..3. In comb. with an aromatase inhib. for tmt. of postmenopausal ptt. with hne.-receptor posit. metast. breast cancer. See Lit
C/I: Hypersens. Sev. dyspnea at rest.
Direct Factor Xa Inhibitor. Rivaroxaban 2.5 mg, 10 mg, 15 mg, 20 mg. FC Tab: 56x 2.5mg, 30 X 10 mg, 28 X 15 mg, 28 X 20 mg
Dosage to be adj. indiv. according to the pt’s. med. condit. See lit.
Rivaroxaban Dexcel 2.5 mg:
Co-admin. with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel, for t prevent. of atherothrombotic events in adult pts. after an acute coron. syndr. (ACS) with elev. cardiac biomarkers.
Co-admin. with acetylsalicylic acid (ASA), for the prevent. of atherothrombotic events in adult pts. with coron. artery dis. (CAD) or symptom. periph. artery dis. (PAD) at high risk of isch. events.
Rivaroxaban Dexcel 10 mg:
Prevent. of venous thromboembolism (VTE) in adult pts. undergoing elective hip or knee replacement surg.
Prevent. of recurrent deep vein thrombosis (DVT) and pulmon. embolism (PE), in adults (following complet. of at least 6 months ther. for DVT or PE).
Rivaroxaban Dexcel 15, 20 mg:
Prevent. of stroke and system. embolism in adult pts. with non-valv. atrial fibrill. with one or more risk factors, such as congestive HF, hypertension, age≥75, diabetes mell., prior stroke or transient isch. attack.
Tmt. of deep vein thrombosis (DVT) and pulmon. embolism (PE), and prevent. of recurr. DVT and PE in adults.
Paed. pop.: Tmt. of venous thromboembolism (VTE) and prevent. of VTE recurr. in children and adolesc. aged less than 18 and weighing from 30 kg to 50 kg after at least 5 days of init. parenteral anticoag. tmt..
C/I-Hypersens.
/Act. clinic. signif. bleeding.
/Lesion or condit., if considered to be a signif. risk for major bleeding. incl. current or recent GI ulcerat., presence of malign. neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surg., recent intracranial haemorrhage, known or suspect. oesophageal varices, arteriovenous malformat., vasc. aneurysms or major intraspin. or intracerebr. vasc. abnormalities.
/ Concomit. tmt. with any other anticoag. e.g. unfraction. heparin (UFH), low MW heparins (enoxaparin, dalteparin, etc.), heparin derivat. (fondaparinux, etc.), oral anticoag. (warfarin, dabigatran etexilate, apixaban, etc.) except under spec. circumst. of switching anticoag. ther. or when UFH is given at doses necess. to maintain an open ctral. venous or arterial catheter.
/Hepatic dis. assoc. with coagulopathy and clinic. relevant bleeding risk incl. cirrhotic p with Child Pugh B and C.
/Pregn. and breastfeed.
For Rivaroxaban Dexcel 2.5mg:
/Concom. tmt. of ACS with antiplatelet ther. in pts. with a prior stroke or a transient isch. attack (TIA).
/Concom. tmt. of CAD/PAD with ASA in pts. with prev. haemorrhagic or lacunar stroke, or any stroke within a month. See lit.
Retinoid. Isotretinoin 5 mg, 10 mg, 20 mg, 40 mg. Soft gel caps 30 X 5/10/20/40 mg
Capsules to be taken with food 1 once or twice /d. Adults and adolescents>12:Start at a dose of 0.5 mg/kg dly. Adjust dose indiv. For most pts., from 0.5-1.0 mg/kg/d. Long-term remission and relapse rates are more closely rel. to total dose admin. than to either duration of tmt. or dly. dose. No substant. addit. benefit to be expected beyond a cumulative dose of 120-150 mg/kg. Duration of tmt. will depend on dly. dose. A tmt. course of 16-24 weeks is normally suffic. to achieve remission. In the majority of pts., complete clearing of acne is obtained with a sgle. course. In the event of a definite relapse at least 8 weeks after discontinuat., a further course may be considered using same dly. and cumulative dose.
For the tmt. of sev. cystic acne that does not respond to other tmt.
C/I: Hypersens.
Pregn. or breastf.
Women of childbearing potent. unless all of the condit. of the Pregn. Prevent. Progr.are met. Teratogenic
• hepatic insuffic.
• excess. elev. blood lipid values
• hypervitaminosis A
• concomitant treatment with tetracyclines
אישור מחדש של חתימות פרוטאומיות מכניות הנלוות לעיכוב SGLT2 בחולים עם אי ספיקת לב
אפיון ומנבאים של שברים בעקבות השתלת תאי גזע המטופוייטים
יעילות טוסיליזומב בטיפול באובאיטיס לא זיהומית
הבדלים בנזק לאיברי המטרה במטופלים עם היפרגליקמיה בינונית וסוכרת
תיאור מקרה: פלישת לימפומה מפושטת שהיתה בהפוגה לשריר הלב
מאפיינים אבחנתיים של גידולי שק החלמון של האשך בילדים
הודעה על עדכון בעלון של התכשירים:
Cresemba 100 mg Capsules - לפרטים נוספים לחץ כאן
Cresemba 200 mg IV - לפרטים נוספים לחץ כאן
Ixifi - לפרטים נוספים לחץ כאן
Xanax X.R - לפרטים נוספים לחץ כאן
Diflucan 50mg/ml-לפרטים נוספים לחצו כאן
Trican 200 mg-לפרטים נוספים לחצו כאן
Triflucan I.V-לפרטים נוספים לחצו כאן
IXIFI-לפרטים נוספים לחצו כאן
Bacterial and Viral Vaccines. RSV F antigen, A+B subgroups 60+60 mcg/ 0.5 ml. Powder and solv. for sol. for IM inject. (60+60 mcg/vial) 1/5/10 doses
A sgle. dose of 0.5 ml to be admin to pregn. women between weeks 24-36 and to persons aged >60. See lit.
• Pass. protect.against lower respir. tract dis. caused by respir. syncytial virus (RSV) in infants from birth through 6 mo. of age following maternal immunisat. during pregn. • Active immunisat. of 60 years of age and older for the prevent. of lower respir. tract disease caused by RSV.
C/I: Hypersens.
Antiretrovirals. Lenacapavir 300 mg. FC tabs 5 X 300 mg
On Day 1 and Day 2, 600 mg Sulenca Tabs. /d taken orally. On Day 8,
300 mg/d taken orally. Then, on Day 15, 927 mg admin by SC inject
In comb. with other antiretroviral(s), for adlts. with multidrug resist. HIV-1 infect. for whom it is not possible to constr. a suppress. anti-viral regimen, for oral loading prior to admin. of long-acting lenacapavir inject.
C/I: Hypersens. Co-admin. with strong inducers of CYP3A, P-gp, and UGT1A1, such as: rifampicin/ carbamazepine, phenytoin/
St. John’s wort (Hypericum perforatum)
Antiretrovirals. Lenacapavir 463.5 mg. Sol for SC inj. Vials 2 X 463.5 mg in 1.5 ml
On Day 1 and Day 2, 600 mg Sulenca Tabs. /d taken orally. On Day 8,
300 mg/d taken orally. Then, on Day 15, 927 mg admin by SC inject. Maint. dose is 927 mg SC inject. every 6 months (26 weeks) from last inject. (+/- 2 weeks).
In comb. with other antiretroviral(s), for the tmt. of adlts with multidrug resist. HIV-1 infect. for whom it is not possible to constr. a suppress. anti-viral regimen.
C/I:Hypersens. Co-admin. with strong inducers of CYP3A, P-gp, and UGT1A1, such as: rifampicin/ carbamazepine, phenytoin/
St. John’s wort (Hypericum perforatum)
Janus Kinase Inhibitor (JAKs). Ritlecitinib 50 mg. Caps. 50 mg X 28
One cap. dly.
Tmt. of sev. alopecia areata in adlts. and adolesc. 12 years and older.
Limit. of Use: Not recomm. in combin. with other JAK inhib., biologic immunomodulat., cyclosporine or other potent immunosuppress.
C/I: Hypersens. Act. ser. infect., incl. TB.
Sev. hep. impairm. Pregn.,breast-feed.
Immunoglobulins. Trastuzumab deruxtecan 20 mg/ml. mAb linked to DXd, an exatecan deriv. and a
topoisomerase I inhibit.
Vial, 100 mg. Powd. for concentr. for sol. for inf.
Breast or Lung cancer: 5.4 mg/kg bw once every 21 days
Gastric cancer: 6.4 mg/kg once every 21 days.
Do not substitute with trastuzumab or ado-trastuzumab emtansine.
HER2-Posit. Metast. Breast Cancer ; HER2-Low Metast. Breast Cancer; Unresect. or Metast. HER2-Mutant Non-Small Cell Lung Cancer; Locally Adv. or Metast. Gastric Cancer. See Lit
C/I: Hypersens.
Human Monoclonal Antibody, Immunoglobulins. Durvalumab 50 mg/ml. Vial: Sol for inf.120/500 mg
Dosage and freq. depend on patient weight, disease type and monoor combined ther. See lit.
Urothelial Carcinoma: for pts with PD-L1 high (Tumor cell ≥25% or IC ≥25%) locally adv. or metast. urothelial carcinoma who:
- have dis. progr. during or following platinum-contain. chemother
. - have dis. progr. within 12 months of neoadj. or adj. tmt with platinum cont. chemother..
Non-Small Cell Lung Cancer - for pts with unresect. Stage III non-small cell lung cancer (NSCLC) whose dis. has not progr. following concurr.platinum-based chemother. and radiation ther.- in comb. with tremelimumab and platinum-based chemother. for the first-line tmt. of adlts with metast. NSCLC with no sensit. EGFR mutat. or ALK pos. mut..
Small Cell Lung Cancer, in combin. with etoposide and either carboplatin or cisplatin, for the first-line tmt. of adlt pts. with extens.-stage small cell lung cancer (ES-SCLC).
Biliary Tract Cancers: in comb. with gemcitabine and cisplatin for the first-line tmt of adlts with locally adv., unresect., or metast. biliary tract cancer (BTC).
Hepatocellular Carcinoma: in comb. with tremelimumab for the first line tmt of adlts with adv. or unresect. hepatocellular carcinoma (HCC).
C/I: Hypersens.
Complement C5a Receptor Inhibitor. Avacopan 30 mg. CAPS 10 mgX30/180
60 mg/d divided into 2 doses.
In comb. with a rituximab or cyclophosphamide regimen, for the
tmt. of adlt. pts. with sev., act. granulomatosis with polyangiitis (GPA) or microsc. polyangiitis (MPA)
C/I: hypersens.
5-α Reductase Inhibitor. Finasteride 1 mg. FC tab. 1 mg X 24
Tab 1/d. Efficacy to be assessed by phys. Grally., 3 or more tmt. months needed before benefit can be observed. Cont. tmt. is recomm. to sustain benefit.
for men with male pattern hair loss (androgenetic alopecia) to incr. hair growth and prevent further hair loss.
C/I: hypersens./women, chld./ Not to be used in combin. with other med. containing finasteride, dutasteride.
Selective β2 Agonist. Salbutamol 5 mg/ml. Sol. for inhal.
Intermittent tmt – Can be given up to 4 times/d.
Adlts and adolesc. aged 12 years and over – 0.5 ml to 1 ml (2.5 to 5 mg salbutamol). Some pts. may req. up to 2 ml (10 mg salbutamol).
Childr. aged 18 months to 12 years – 0.5 ml to 1 ml (2.5 to 5 mg salbutamol).
tmt. of sev. acute asthma (status asthmaticus) and other forms of bronchospasm
C/I: Hypersens.
